PALO ALTO, Calif. and NEW YORK — September 8, 2026
Evommune, Inc. announced top-line results from its randomized, double-blind, placebo-controlled Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis (AD), with the study failing to meet its primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12. The trial enrolled 121 adults and evaluated multiple doses of the oral MRGPRX2 antagonist over 12 weeks, with follow-up continuing through Week 14. EVO756 did not meet the primary or secondary efficacy endpoints at any dose evaluated. Based on the results, Evommune said it does not plan to advance EVO756 in atopic dermatitis, marking a strategic change for the program while maintaining its broader focus on chronic inflammatory diseases. Despite the efficacy setback, EVO756 was generally well tolerated, with a safety profile consistent with previous studies.
EVO301 Becomes Evommune’s Lead Atopic Dermatitis Program
Following the EVO756 results, Evommune is shifting its lead atopic dermatitis development focus to EVO301, its long-acting injectable SAFA-IL-18BP fusion protein. The company recently reported positive Phase 2a proof-of-concept data for EVO301, supporting plans to initiate a Phase 2b study in atopic dermatitis around mid-2027. EVO301 is designed to neutralize aberrantly elevated IL-18 activity and incorporates a series of molecular design features intended to improve tissue distribution, binding characteristics and duration of action. The molecule combines native human IL-18BP with serum albumin binding to provide an extended half-life while maintaining selective IL-18 neutralization. Evommune believes the differentiated modality could offer a new approach to chronic inflammatory diseases and provide the company with a replacement development pathway in AD following the discontinuation of EVO756 for this indication.
EVO756 Continues Development in Migraine Prevention
Although EVO756 will no longer advance in atopic dermatitis, Evommune plans to continue its Phase 2b development in migraine prophylaxis, preserving a clinical development path for the MRGPRX2-targeted therapy. EVO756 is a potent and highly selective oral small-molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly expressed on mast cells and peripheral sensory neurons. The mechanism is being investigated as a potential approach to chronic inflammatory conditions and migraine. The decision to discontinue the AD program follows the absence of efficacy across all doses tested rather than a reported tolerability concern. By maintaining development in migraine prevention while redirecting its AD strategy toward EVO301, Evommune is seeking to maximize the value of its clinical-stage assets while concentrating resources on programs with stronger proof-of-concept support.
Advertisement
Evommune Maintains Broader Inflammation Pipeline Strategy
The EVO756 Phase 2b outcome reshapes Evommune’s near-term portfolio priorities but does not alter the company’s broader strategy to develop differentiated therapies for chronic inflammatory diseases. Evommune said its balance sheet is expected to support operations into 2029, providing financial capacity to continue advancing its pipeline while moving EVO301 toward Phase 2b development. The company’s approach centers on targeting biological drivers of chronic inflammation through differentiated mechanisms and therapeutic modalities. EVO301 is now positioned as the company’s principal AD program, while EVO756 remains active in migraine prophylaxis. The shift illustrates Evommune’s strategy of reallocating development resources following clinical readouts and prioritizing candidates supported by stronger clinical evidence. With EVO301 advancing toward a planned Phase 2b study and EVO756 continuing in migraine, Evommune is maintaining a diversified clinical pipeline while narrowing its focus within atopic dermatitis.
Source: Evommune, ,press release
